Cargando...
Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
Recently, we reported on potent EphA2 targeting compounds and demonstrated that dimeric versions of such agents can exhibit remarkably increased agonistic activity in cellular assays compared to the monomers. Here we further characterize the activity of dimeric compounds at the structural, biochemic...
Guardado en:
| Publicado en: | Pharmaceuticals (Basel) |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7281375/ https://ncbi.nlm.nih.gov/pubmed/32397624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13050090 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|